IBRX: ImmunityBio Corp Net earnings per share (EPS TTM)
ImmunityBio, Inc. (IBRX) delegates the development and production of drugs to external contractors, yet its bladder cancer therapy is already generating a steady cash flow. The trailing twelve-month earnings per share reconciles these aspects, where the -0.97 mark reflects the latest data. Strong pricing power and the uniqueness of NK-cell activation provide the company with exceptional market control.
Summary analytical data breakdowns for ImmunityBio Inc (IBRX)
- share price and expert price forecast:
- market capitalization information:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio ImmunityBio, Inc.|IBRX - Long-Term Debt to Capital|Short-Term Debt to Equity ImmunityBio Corp|IBRX - Company Aggregate Debt|Debt to Book Capitalization Ratio ImmunityBio, Inc.|IBRX - Long-Term Debt|Company Current Liabilities ImmunityBio|Quick Liquidity Indicator immunitybio.com
- earnings and multiples data:
IBRX - Profit After Payment of Taxes|Projected Future Earnings ImmunityBio, Inc.|IBRX - Company Value to Net Income|Forward P/E Multiple ImmunityBio|IBRX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ImmunityBio, Inc.|IBRX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) ImmunityBio|IBRX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months immunitybio.com|IBRX - Earnings per share trend in current year|Expected earnings per share growth for next year ImmunityBio, Inc.
Fundamental valuation:IBRX - ImmunityBio, Inc.
The efficiency of implementing robotic bioreactors and AI platforms into drug synthesis directly impacts the ability of ImmunityBio, Inc. (IBRX) to generate real earnings per share. Analyzing changes in per-share profit over the last 12 months allows for an assessment of the rolling annual return on capital, adjusted for the total number of shares, which helps investors differentiate fundamental growth from speculative price inflation.
Main competitors
IMCR: Net earnings per share for the last 12 months|Earnings per share for the trailing year JANX (januxrx.com)|RCUS: Net earnings per share (EPS TTM)|ZYME - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Tango Pharma|Net earnings per share for the last 12 months Iovance Corp (IOVA)|Earnings per share for the last twelve months Immatics N.V. (IMTX)|Net earnings per share for the last 12 months xencor.com XNCR|Compass Therapeutics, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Replimune Group Inc REPL|LYEL - Earnings per share for the last twelve months|IPHA (Innate Pharma S.A) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma)|Earnings per share for the trailing year ALXO|Cue Biopharma, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months PDS Biotechnology|sonnetbio.com (SONN) - Earnings per share for the last twelve months|MAIA Bio - Earnings per share for the trailing year|LIMN (Liminatus Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Lava Tx|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics Inc (SNSE) - Net earnings per one share for the last twelve months|Theriva Biologics, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Gritstone bio, Inc. GRTS|Kineta (KA) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months NexImmune Inc|Earnings per share for the last twelve months Turnstone Biologics Corp|Net earnings per share for the last 12 months Vaccinex Inc (VCNX)|Net earnings per share for the last 12 months HARP (Harpoon Therapeutics)
